Related Experiment Video
Updated: Apr 14, 2026
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
A Twelve-Week Follow-up Study of Obesity, Antioxidant Enzyme Activity, and Clinical Symptoms in First-Episode
Jing Yao1, Cheng Zhu2, Fei Wang3
1Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Objective:
Overweight/obesity is highly prevalent in schizophrenia (Sch), which can perturb brain function and correlate with symptom severity. An impaired antioxidant defense system is involved in the pathophysiology of Sch and obesity. This longitudinal study aimed to investigate the impact of overweight/obesity on the antioxidant enzymes and the response to risperidone in patients with Sch.
Methods:
Two hundred and sixty-nine patients with Sch were recruited and received 12-week treatment with risperidone. Clinical symptoms, weight, and antioxidant enzyme were measured at baseline and week 12.
Results:
Non-obese patients with Sch showed decreased GSHPx activity after treatment with risperidone but no difference in obese patients. In obese patients, GSHPx activity was associated with an improvement in positive symptoms. Meanwhile, in non-obese patients, a reduction in GSHPx activity was correlated with an improvement in general psychology.
Conclusion:
This study suggests that obesity at the onset influences the improvement in the clinical symptoms after treatment with risperidone in patients with Sch, which is related to its modulations on GSHPx.
More Related Videos
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
01:29Psychological and Sociocultural Causes of Schizophrenia